## QSAR model: prediction of the clastogenic potential of 3-arylcoumarins

Estela Guardado Yordi<sup>1,2</sup>, Amaury Pérez<sup>3</sup>, Lianne León<sup>2</sup>, Enrique Molina<sup>1,2</sup>, Lourdes Santana,<sup>1</sup> Eugenio Uriarte<sup>1,4</sup> and Maria João Matos<sup>1\*</sup>

<sup>1</sup> <u>Universidad de Santiago de</u> Compostela, Facultad de Farmacia, Campus vida, 15782 Santiago de Compostela, Spain <sup>2</sup> Universidad de Camagüey Ignacio Agramonte Loynaz, Facultad de Ciencias Aplicadas, Cincunvalación Norte Km 5 1/2, Camagüey, Cuba <sup>3</sup> Universidad Estatal Amazónica, Facultad de Ciencias de la Tierra, Km 2 1/2 vía Puyo a Tena (Paso Lateral), Puyo, Ecuador

<sup>4</sup> Instituto de Química Aplicada, Universidad Autónoma de Chile, Pedro de Valdivia 425, 7500912 Santiago, Chile

\* E-mail: mariajoao.correiapinto@usc.es

Abstract. Drug discovery is a challenging task for researchers due to the complexity of biomolecules involved in pathologic processes. Design and development of efficient drugs is still urgent for several diseases. Cheminformatics tools are useful to better understand the interaction between new chemical entities and their targets. We studied a selected series of 3-arylcoumarins with antioxidant potential, and how their chemical features can contribute for the clastogenic activity. A virtual screening, based on the TOPSMODE approach, using a clastogenic model, was performed. The results suggest that the presence and position of hydroxyl groups in the scaffold is important for the activity. This communication is focused on cheminformatics, and its applications in drug effectiveness and safety. Keywords. 3-Arylcoumarins; Clastogenicity; TOPSMODE; Cheminformatics.

Introduction



Specially 3-arylcoumarins, have been studied. Part of this series of coumarins, and some new ones, form the basis of new research that has been based on previous results related to the safety of natural coumarins in food sources and the use of computational toxicology. To increase the safety of these molecules as potential drugs, the present work aims to predict clastogenic



Results



Inactive m

Figure 2. Example of in silico 3-arylcoumarins predicted

as active/inactive. \* prediction of this coumarin was

previously published.

	Table 1. External Dataset and prediction							
mpound	R <sub>7</sub>	R <sub>8</sub>	R <sub>2</sub> .	R <sub>3</sub> .	R <sub>4</sub> .	₽ <sub>5</sub> .	Prob.*	Class
1	Н	ОН	Н	Н	н	н	75.7	G1:-1
2	н	ОН	Н	н	ОН	н	67.1	G1:-1
3	н	OH	н	OH	н	н	67.0	G1:-1
4	н	ОН	н	OH	ОН	н	52.7	G1:-1
5	н	ОН	ОН	Н	н	н	64.4	G1:-1
6	н	ОН	н	н	Me	н	79.4	G1:-1
7	ОН	Н	Н	Н	Me	н	82.1	G1:-1
8	ОН	ОН	н	н	н	н	62.6	G1:-1
9	ОН	Н	Н	ОН	н	н	70.5	G1:-1
10	ОН	ОН	Н	Н	Н	ОН	52.4	G1:-1
11	ОН	OH	ОН	н	Н	Н	50.6	G2:1
12	ОН	OH	н	н	ОН	ОН	62.7	G2:1
13	ОН	н	н	н	н	Br	74.1	G1:-1
14	ОН	ОН	Н	Н	ОН	Н	52.2	G1:-1
15	ОН	н	ОН	н	н	н	68.1	G1:-1
16	ОН	н	н	н	н	н	70.6	G1:-1

Figure 3. 3-Arylcoumarins with high in vitro antioxidant activity (predicted as non clastogenic in silico).



These compounds presented high antioxidant activity in ORAC-FL studies, are significant for the future work of the research group. These compounds could become future antioxidants for several uses

This structural fragment must be considered in the design of new derivatives, since the clastogenic model used in previous studies carried out with natural coumarins recognizes methyl substituents as important chemical feature for the compounds to be non-clastogenic

pharmaceuticals

## Conclusions

The preliminary interpretation of the relationship between structure and clastogenicity, considering this external dataset, suggests the importance of hydroxyl groups in the coumarin ring at 7 and/or 8 positions. In general, a tendency to be clastogenic was observed for polyhydroxylated coumarins (specially positions 7 and 8, together with a catechol group in the 3-phenyl group. Future work of SAR is required, for which it is necessary to expand the dataset and the experimental studies that allow to validate these predictions.

References

## 1. Muñoz, A.; Fonseca, A.; Matos, M.J.; Uriarte, E.; Santana, L.; Borges, F.; Figueroa , R.; Olea-Azar, C. ChemistrySelect 2016 2. Matos, M.J.; Mura, F.; Vazquez-Rodriguez, S.; Borges, F.; Santana, L.; Uriarte, E.; Olea-Azar, C. Molecules 2015, 20

 Figueroa-Guinez, R.; Matos, M.J.; Vazquez-Rodriguez, S.; Santana, L.; Uriarte, E.; Olea-Azar C\*; Borges, F.; Diego Maya, J. Curr Top Med Chem 2015, 15, 850-856. 4. Venugopala, K.N.; Rashmi, V.; Odhav, B. BioMed Research International 2013, 2013, 1-14

rdi, E.; Matos, M.J.; Santana, L.; Uriarte, E.; Abreu, O.; Molina, E. Biological and Chemical Research 2015,

MDPI

sponsors:

olume 2015, 241-257 Guardad - Y di, E.; Matos, M.J.; Castro, R.; Santana, L.; Uriarte, E.; Molina, E. LWT - Food Science and Technology 2015. 61.216-223



Active molecule:

**3rd International Electronic Conference** on Medicinal Chemistry 1-30 November 2017